<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://biotechmorning.com/news/moderna-mrna-flu-vaccine-fda-decision</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-03T14:20:33.247Z</news:publication_date>
      <news:title>The Flu Shot Hasn&apos;t Changed in Decades. That Might End Tuesday.</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/arpa-h-160-million-gene-editing-thrive-program</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-03T14:19:40.505Z</news:publication_date>
      <news:title>The $160 Million Bet That Could Turn One-Patient Miracles Into a Playbook</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/replimune-rp1-fda-rejection-melanoma-stock-crash</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-03T14:18:50.013Z</news:publication_date>
      <news:title>The Virus That Couldn&apos;t Catch a Break</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/elevidys-gene-therapy-liver-failure-deaths-fda-investigation</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-03T14:17:55.195Z</news:publication_date>
      <news:title>The Gene Therapy That Saved Kids&apos; Muscles May Be Destroying Their Livers</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/fda-oncology-trial-eligibility-guidances-2026</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-02T14:22:47.501Z</news:publication_date>
      <news:title>The FDA Just Blew Open the Doors to Cancer Clinical Trials</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/tepezza-lost-monopoly-viridian-lumvoa-approval</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-02T14:22:02.546Z</news:publication_date>
      <news:title>Tepezza Just Lost Its $1.9 Billion Monopoly</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/one-dose-lsd-beat-every-antidepressant</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-02T14:21:05.985Z</news:publication_date>
      <news:title>One Dose of LSD Just Beat Every Antidepressant on the Market</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/lilly-abbisko-china-oncology-deal</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-02T14:20:14.082Z</news:publication_date>
      <news:title>Lilly Just Bet $1.9B on a Shanghai Biotech. In This Political Climate.</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/lantheus-cancer-imaging-fda-manufacturing-rejection</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-02T14:19:20.907Z</news:publication_date>
      <news:title>Lantheus Built a Better Cancer Scanner. The Factory Couldn&apos;t Keep Up.</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/ebola-bundibugyo-strain-vaccine-race</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-02T14:18:40.616Z</news:publication_date>
      <news:title>The Ebola Strain Nobody Had a Vaccine For Just Became a Global Emergency</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/fda-shaved-year-off-drug-timeline</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-02T14:17:52.796Z</news:publication_date>
      <news:title>The FDA Just Shaved a Year Off Your Drug&apos;s Timeline</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/fda-real-time-clinical-trial-monitoring-pilot</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-02T14:16:57.406Z</news:publication_date>
      <news:title>The FDA Wants to Watch Your Clinical Trial Live. Yes, Really.</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/oruka-one-shot-psoriasis-beats-skyrizi</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-02T14:16:05.237Z</news:publication_date>
      <news:title>One Shot a Year: The Tiny Biotech That Just Embarrassed AbbVie&apos;s $18B Drug</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/intellia-crispr-phase-3-fda-filing</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-02T14:15:13.846Z</news:publication_date>
      <news:title>One Shot to Edit Your DNA Forever. The FDA Might Say Yes.</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/ipsen-two-acquisitions-one-week-rare-disease</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-01T14:23:47.679Z</news:publication_date>
      <news:title>Ipsen Just Spent $2.5 Billion in One Week. Here&apos;s What They&apos;re Chasing.</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/astrazeneca-cspc-kidney-disease-sirna-deal</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-01T14:22:54.586Z</news:publication_date>
      <news:title>AstraZeneca&apos;s $1.77B Bet on a Chinese Partner Nobody Expected</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/novo-inflammation-drug-trial-failure</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-01T14:22:03.104Z</news:publication_date>
      <news:title>Novo&apos;s Big Bet on Inflammation Just Went Up in Smoke</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://biotechmorning.com/news/lilly-2-3-billion-ajax-jak-inhibitor-deal</loc>
    <news:news>
      <news:publication>
        <news:name>Biotech Morning</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-01T14:21:14.900Z</news:publication_date>
      <news:title>Lilly Just Bet $2.3 Billion That a Failed Drug Class Deserves a Second Chance</news:title>
    </news:news>
  </url>
</urlset>